Molecular biology and pathogenesis of viral myocarditis

Annual Review of Pathology: Mechanisms of Disease

Volumn 3, Issue , 2008, Pages 127-155

  Esfandiarei, Mitra ^a,b   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CVB3 pathogenesis; CVB3 induced apoptosis; Host cell signaling; Immune response; Myocardial injury

Indexed keywords

CASPASE; CYTOKINE; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PERFORIN; PROTEASE 3C; PROTEIN CAR; PROTEIN TYROSINE KINASE; PROTEIN VP1; PROTEINASE; PROTEINASE 2A; RNA; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENZYME;

ADAPTIVE IMMUNITY; APOPTOSIS; BIOSTATISTICS; CARDIOMYOPATHY; CELL INFILTRATION; CLINICAL EVALUATION; CLINICAL FEATURE; COXSACKIE VIRUS B3; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; GENOMICS; HEART MUSCLE INJURY; HISTOPATHOLOGY; HOST CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFORMATION SCIENCE; INNATE IMMUNITY; MOLECULAR BIOLOGY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; VIRUS; VIRUS ENTRY; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ANIMALS; AUTOIMMUNE DISEASES; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; FEMALE; GENOMICS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, NATURAL; INFANT, NEWBORN; MICE; MIDDLE AGED; MOLECULAR BIOLOGY; MYOCARDITIS; PROTEOMICS;

EID: 41749107345     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathmechdis.3.121806.151534     Document Type: Review

References (150)

1. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, et al. 1987. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1:3-14
2. McManus BM, Kandolf R. 2000. Myocarditis. In Atlas of Cardiovascular Pathology for the Clinician, ed. BM McManus, pp. 168-83. Philadelphia: Curr. Med.
3. Morris SA, Tanowitz HB, Wittner M, Bilezikian JP. 1990. Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 82:1900-9
4. Grist NR, Reid D. 1997. Organisms in myocarditis/endocarditis viruses. J. Infect. 34:155
5. Froeschle JE, Feorino PM, Gelfand HM. 1966. A continuing surveillance of enterovirus infection in healthy children in six United States cities. II. Surveillance enterovirus isolates 1960-1963 and comparison with enterovirus isolates from cases of acute central nervous system disease. Am. J. Epidemiol. 83:455-69
6. Abelmann WH. 1971. Virus and the heart. Circulation 44:950-56
7. Reyes MP, Lerner AM. 1985. Coxsackievirus myocarditis - with special reference to acute and chronic effects. Prog. Cardiovasc. Dis. 27:373-94
8. McManus BM, Gauntt CJ, Cassling RS. 1988. Immunopathological basis of myocardial injury. In Contemporary Issues in Cardiovsacular Pathology, ed. BF Waller, pp. 163-84. Philadelphia: Davis
9. Mason JW. 1978. Techniques for right and left ventricular endomyocardial biopsy. Am. J. Cardiol. 41:887-92
10. Aretz HT. 1987. Myocarditis: the Dallas criteria. Hum. Pathol. 18:619-24
11. Billingham ME. 1985. The diagnostic criteria of myocarditis by endomyocardial biopsy. Heart Vessels Suppl. 1:133-37
12. Nippoldt TB, Edwards WD, Holmes DR Jr, Reeder GS, Hartzler GO, Smith HC. 1982. Right ventricular endomyocardial biopsy: clinicopathologic correlates in 100 consecutive patients. Mayo Clin. Proc. 57:407-18
13. Vasiljevic JD, Kanjuh V, Seferovic P, Sesto M, Stojsic D, Olsen EG. 1990. The incidence of myocarditis in endomyocardial biopsy samples from patients with congestive heart failure. Am. Heart J. 120:1370-77
14. Herskowitz A, Campbell S, Deckers J, Kasper EK, Boehmer J, et al. 1993. Demographic features and prevalence of idiopathic myocarditis in patients undergoing endomyocardial biopsy. Am. J. Cardiol. 71:982-86
15. Shanes JG, Ghali J, Billingham ME, Ferrans VJ, Fenoglio JJ, et al. 1987. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation 75:401-5
16. Martino T, Liu P, Sole MJ. 1995. Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies. In Human Enterovirus Infections, ed. H Robart, pp. 291-51. Washington, DC: ASM
17. Lyden DC, Olszewski J, Feran M, Job LP, Huber SA. 1987. Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am. J. Pathol. 126:432-38
18. Huber SA, Pfaeffle B. 1994. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 68:5126-32
19. Beck MA, Levander OA, Handy J. 2003. Selenium deficiency and viral infection. J. Nutr. 133(Suppl. 1):S1463-67
20. Okuni M, Yamada T, Mochizuki S, Sakurai I. 1975. Studies on myocarditis in childhood, with special reference to the possible role of immunological process and the thymus in the chronicity of the disease. Jpn. Circ. J. 39:463-70
21. Drory Y, Turetz Y, Hiss Y, Lev B, Fisman EZ, et al. 1991. Sudden unexpected death in persons less than 40 years of age. Am. J. Cardiol. 68:1388-92
22. Kim KS, Hufnagel G, Chapman NM, Tracy S. 2001. The group B coxsackieviruses and myocarditis. Rev. Med. Virol. 11:355-68
23. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. 1991. Clinicopathologic description of myocarditis. J. Am. Coll. Cardiol. 18:1617-26
24. Olsen EG. 1993. Morphological recognition of viral heart disease. Scand. J. Infect. Dis. Suppl. 88:45-47
25. Fohlman J, Pauksen K, Hyypia T, Eggertsen G, Ehrnst A, et al. 1996. Antiviral treatment with WIN 54954 reduces mortality in murine coxsackievirus B3 myocarditis. Circulation 94:2254-59
26. Makarov VA, Riabova OB, Granik VG, Wutzler P, Schmidtke M. 2005. Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J. Antimicrob. Chemother. 55:483-88
27. Bauer S, Gottesman G, Sirota L, Litmanovitz I, Ashkenazi S, Levi I. 2002. Severe Coxsackie virus B infection in preterm newborns treated with Pleconaril. Eur. J. Pediatr. 161:491-93
28. See DM, Tilles JG. 1994. Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses. Scand. J. Infect. Dis. 26:739-47
29. Gauntt CJ, Paque RE, Trousdale MD, Gudvangen RJ, Barr DT, et al. 1983. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis. Infect. Immun. 39:851-64
30. Fohlman J, Pauksen K, Morein B, Bjare U, Ilback NG, Friman G. 1993. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand. J. Infect. Dis. Suppl. 88:103-8
31. Dan M, Chantier JK. 2005. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection. J. Virol. 79:9285-95
32. Henke A, Wagner E, Whitton JL, Zell R, Stelzner A. 1998. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J. Virol. 72:8327-31
33. Hunziker IP, Harkins S, Feuer R, Cornell CT, Whitton JL. 2004. Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge. Virology 330:196-208
34. Rabin ER, Hassan SA, Jenson AB, Melnick JL. 1964. Coxsackievirus B3 myocarditis in mice. An electron microscopic, immunofluorescent and virus-assay study. Am. J. Pathol. 44:775-97
35. Melnick JL, Godman GC. 1951. Pathogenesis of coxsackievirus infection; multiplication of virus and evolution of the muscle lesion in mice. J. Exp. Med. 93:247-66
36. Chow LH, Gauntt CJ, McManus BM. 1991. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab. Invest. 64:55-64
37. McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, et al. 1993. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin. Immunol. Immunopathol. 68:159-69
38. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y. 1997. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus B3. J. Pathol. 183:105-8
39. Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, et al. 2005. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112:2276-85
40. Cho CT, Feng KK, McCarthy VP, Lenahan MF. 1982. Role of antiviral antibodies in resistance against coxsackievirus B3 infection: interaction between preexisting antibodies and an interferon inducer. Infect. Immun. 37:720-27
41. Tomioka N, Kishimoto C, Matsumori A, Kawai C. 1986. Effects of prednisolone on acute viral myocarditis in mice. J. Am. Coll. Cardiol. 7:868-72
42. Godeny EK, Gauntt CJ. 1986. Involvement of natural killer cells in coxsackievirus B3-induced murine myocarditis. J. Immunol. 137:1695-702
43. Godeny EK, Gauntt CJ. 1987. Murine natural killer cells limit coxsackievirus B3 replication. J. Immunol. 139:913-18
44. Koike H, Kanda T, Sumino H, Yokoyama T, Arai M, et al. 2001. Reduction of viral myocarditis in mice lacking perforin. Res. Commun. Mol. Pathol. Pharmacol. 110:229-37
45. Kishimoto C, Kuribayashi K, Masuda T, Tomioka N, Kawai C. 1985. Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation 71:1247-54
46. Seko Y, Tsuchimochi H, Nakamura T, Okumura K, Naito S, et al. 1990. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with coxsackievirus B3. Circ. Res. 67:360-67
47. Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, et al. 1993. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J. Clin. Invest. 91:1327-36
48. Huber SA, Stone JE, Wagner DH Jr, Kupperman J, Pfeiffer L, et al. 1999. γ δ T cells regulate major histocompatibility complex class II(IA and IE)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis. J. Virol. 73:5630-36
49. Kyu B, Matsumori A, Sato Y, Okada I, Chapman NM, Tracy S. 1992. Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy. Circulation 86:522-30
50. Li Y, Bourlet T, Andreoletti L, Mosnier JF, Peng T, et al. 2000. Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation 101:231-34
51. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, et al. 1992. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. USA 89:314-18
52. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. 1994. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 72:561-66
53. Gillespie JS, Cavanagh HM, Behan WM, Morrison LJ, McGarry F, Behan PO. 1993. Increased transcription of interleukin-6 in the brains of mice with chronic enterovirus infection. J. Gen. Virol. 74:741-43
54. Gluck B, Schmidtke M, Merkle I, Stelzner A, Gemsa D. 2001. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J. Mol. Cell Cardiol. 33:1615-26
55. Baboonian C, Davies MJ, Booth JC, McKenna WJ. 1997. Coxsackie B viruses and human heart disease. Curr. Top. Microbiol. Immunol. 223:31-52
56. Dalldorf G. 1955. The coxsackie viruses. Annu. Rev. Microbiol. 9:277-96
57. Baboonian C, Treasure T. 1997. Meta-analysis of the association of enteroviruses with human heart disease. Heart 78:539-43
58. Grumbach IM, Heim A, Pring-Akerblom P, Vonhof S, Hein WJ, et al. 1999. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol. 54:83-88
59. Peng T, Li Y, Yang Y, Niu C, Morgan-Capner P, et al. 2000. Characterization of enterovirus isolates from patients with heart muscle disease in a selenium-deficient area of China. J. Clin. Microbiol. 38:3538-43
60. Nicholson-Weller A, Wang CE. 1994. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123:485-91
61. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM. 1992. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn1. J. Immunol. 149:3535-41
62. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, et al. 2000. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat. Med. 6:429-34
63. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. 2001. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. USA 98:15191-96
64. Wang X, Bergelson JM. 1999. Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J. Virol. 73:2559-62
65. Yanagawa B, Spiller OB, Choy J, Luo H, Cheung P, et al. 2003. Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab. Invest. 83:75-85
66. Yanagawa B, Spiller OB, Proctor DG, Choy J, Luo H, et al. 2004. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus B3-mediated pancreatitis and myocarditis in mice. J. Infect. Dis 189:1431-39
67. Goodfellow IG, Evans DJ, Blom AM, Kerrigan D, Miners JS, et al. 2005. Inhibition of Coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J. Virol. 79:12016-24
68. Coyne CB, Bergelson JM. 2006. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124:119-31
69. Tomko RP, Xu R, Philipson L. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94:3352-56
70. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, et al. 1998. The murine CAR homolog is a receptor for Coxsackie B viruses and adenoviruses. J. Virol. 72:415-19
71. Honda T, Saitoh H, Masuko M, Katagiri-Abe T, Tominaga K, et al. 2000. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res. Mol. Brain Res. 77:19-28
72. Cheung PK, Yuan J, Zhang HM, Chau D, Yanagawa B, et al. 2005. Specific interactions of mouse organ proteins with the 5′ untranslated region of coxsackievirus B3: potential determinants of viral tissue tropism. J. Med. Virol. 77:414-24
73. Flanegan JB, Petterson RF, Ambros V, Hewlett NJ, Baltimore D. 1977. Covalent linkage of a protein to a defined nucleotide sequence at the 5′-terminus of virion and replicative intermediate RNAs of poliovirus. Proc. Natl. Acad. Sci. USA 74:961-65
74. Pelletier J, Kaplan G, Racaniello VR, Sonenberg N. 1988. Cap-independent translation of poliovirus mRNA is conferred by sequence elements within the 5′ noncoding region. Mol. Cell Biol. 8:1103-12
75. Jacobson MF, Baltimore D. 1968. Polypeptide cleavages in the formation of poliovirus proteins. Proc. Natl. Acad. Sci. USA 61:77-84
76. Wimmer E, Hellen CU, Cao X. 1993. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436
77. Hellen CU, Lee CK, Wimmer E. 1992. Determinants of substrate recognition by poliovirus 2A proteinase. J. Virol. 66:3330-38
78. Ziegler E, Borman AM, Deliat FG, Liebig HD, Jugovic D, et al. 1995. Picornavirus 2A proteinase-mediated stimulation of internal initiation of translation is dependent on enzymatic activity and the cleavage products of cellular proteins. Virology 213:549-57
79. Ehrenfeld E. 1982. Poliovirus-induced inhibition of host-cell protein synthesis. Cell 28:435-36
80. Ventoso I, MacMillan SE, Hershey JW, Carrasco L. 1998. Poliovirus 2A proteinase cleaves directly the eIF-4G subunit of eIF-4F complex. FEBS Lett. 435:79-83
81. Chau D, Yuan J, Zhang H, Cheung P, Lim T, et al. 2007. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis 12:513-24
82. Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, et al. 1999. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5:320-26
83. Clark ME, Lieberman PM, Berk AJ, Dasgupta A. 1993. Direct cleavage of human TATA-binding protein by poliovirus protease 3C in vivo and in vitro. Mol. Cell Biol. 13:1232-37
84. Yalamanchili P, Datta U, Dasgupta A. 1997. Inhibition of host cell transcription by poliovirus: cleavage of transcription factor CREB by poliovirus-encoded protease 3Cpro. J. Virol. 71:1220-26
85. Yalamanchili P, Weidman K, Dasgupta A. 1997. Cleavage of transcriptional activator Oct-1 by poliovirus encoded protease 3Cpro. Virology 239:176-85
86. Van Dyke TA, Flanegan JB. 1980. Identification of poliovirus polypeptide P63 as a soluble RNA-dependent RNA polymerase. J. Virol. 35:732-40
87. Paul AV, van Boom JH, Filippov D, Wimmer E. 1998. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393:280-84
88. Novak JE, Kirkegaard K. 1991. Improved method for detecting poliovirus negative strands used to demonstrate specificity of positive-strand encapsidation and the ratio of positive to negative strands in infected cells. J. Virol. 65:3384-87
89. Doedens JR, Kirkegaard K. 1995. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J. 14:894-907
90. van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, et al. 1997. Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J. 16:3519-32
91. Johnson KL, Sarnow P. 1991. Three poliovirus 2B mutants exhibit noncomplementable defects in viral RNA amplification and display dosage-dependent dominance over wildtype poliovirus. J. Virol. 65:4341-49
92. Woodruff JF, Woodruff JJ. 1974. Involvement of T lymphocytes in the pathogenesis of coxsackievirus B3 heart disease. J. Immunol. 113:1726-34
93. Opavsky MA, Penninger J, Aitken K, Wen WH, Dawood F, et al. 1999. Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection. Circ. Res. 85:551-58
94. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, et al. 1989. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N. Engl. J. Med. 321:1061-68
95. Maisch B, Schonian U, Hengstenberg C, Herzum M, Hufnagel G, et al. 1994. Immunosuppressive treatment in autoreactive myocarditis: results from a controlled trial. Postgrad. Med. J. 70(Suppl. 1):S29-34
96. Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, et al. 1995. The Myocarditis Treatment Trial: design, methods and patients enrollment. Eur. Heart J. 16(Suppl. O):162-67
97. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, et al. 1995. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 333:269-75
98. Brown CA, O'Connell JB. 1996. Implications of the Myocarditis Treatment Trial for clinical practice. Curr. Opin. Cardiol. 11:332-36
99. Maisch B, Hufnagel G, Schonian U, Hengstenberg C. 1995. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur. Heart J. 16(Suppl. 0):173-75
100. Hufnagel G, Pankuweit S, Richter A, Schonian U, Maisch B. 2000. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 25:279-85
101. Garg A, Shiau J, Guyatt G. 1998. The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis: an overview. Annu. Intern. Med. 129:317-22
102. Hia CP, Yip WC, Tai BC, Quek SC. 2004. Immunosuppressive therapy in acute myocarditis: an 18 year systematic review. Arch. Dis. Child. 89:580-84
103. Nishio R, Matsumori A, Shioi T, Ishida H, Sasayama S. 1999. Treatment of experimental viral myocarditis with interleukin-10. Circulation 100:1102-8
104. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, et al. 2003. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793-98
105. Huber SA, Lodge PA. 1984. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am. J. Pathol. 116:21-29
106. Huber SA. 1997. Autoimmunity in myocarditis: relevance of animal models. Clin. Immunol. Immunopathol. 83:93-102
107. Schultheiss HP, Berg P, Klingenberg M. 1983. The mitochondrial adenine nucleotide translocator is an antigen in primary biliary cirrhosis. Clin. Exp. Immunol. 54:648-54
108. Wolff PG, Kuhl U, Schultheiss HP. 1989. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am. Heart J. 117:1303-9
109. De Scheerder IK, De Buyzere M, Delanghe J, Maas A, Clement DL, Wieme R. 1991. Humoral immune response against contractile proteins (actin and myosin) during cardiovascular disease. Eur. Heart J. 12(Suppl. D):88-94
110. Caforio AL, Goldman JH, Haven AJ, Baig KM, Libera LD, McKenna WJ. 1997. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur. Heart J. 18:270-75
111. Schwimmbeck PL, Badorff C, Rohn G, Schulze K, Schultheiss HP. 1996. The role of sensitized T-cells in myocarditis and dilated cardiomyopathy. Int. J. Cardiol. 54:117-25
112. Latif N, Zhang H, Archard LC, Yacoub MH, Dunn MJ. 1999. Characterization of anti-heart antibodies in mice after infection with Coxsackie B3 virus. Clin. Immunol. 91:90-98
113. Rose NR, Hill SL. 1996. The pathogenesis of postinfectious myocarditis. Clin. Immunol. Immunopathol. 80:S92-99
114. Takata S, Nakamura H, Umemoto S, Yamaguchil K, Sekine T, et al. 2004. Identification of autoantibodies with the corresponding antigen for repetitive coxsackievirus infection-induced cardiomyopathy. Circ. J. 68:677-82
115. Gauntt CJ, Arizpe HM, Higdon AL, Wood HJ, Bowers DF. 1995. Molecular mimicry, anticoxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. J. Immunol. 154:2983-95
116. Maisch B, Bauer E, Cirsi M, Kochsiek K. 1993. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation 87(Suppl. 5):49-65
117. Fairweather D, Rose N. 2007. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 41:118-22
118. Hofschneider PH, Klingel K, Kandolf R. 1990. Toward understanding the pathogenesis of enterovirus-induced cardiomyopathy: molecular and ultrastructural approaches. J. Struct. Biol. 104:32-37
119. Gomez RM, Lopez Costa JJ, Pecci Saavedra G, Berria MI. 1993. Ultrastructural study of cell injury induced by coxsackievirus B3 in pancreatic and cardiac tissues. Mediana (B Aires) 53:300-6
120. Carthy CM, Granville DJ, Watson KA, Anderson DR, Wilson JE, et al. 1998. Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J. Virol. 72:7669-75
121. Henke A, Launhardt H, Klement K, Stelzner A, Zell R, Munder T. 2000. Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva. J. Virol. 74:4284-90
122. Martin U, Nestler M, Munder T, Zell R, Sigusch HH, Henke A. 2004. Characterization of coxsackievirus B3-caused apoptosis under in vitro conditions. Med. Microbiol. Immunol. 193:133-39
123. Saraste A, Arola A, Vuorinen T, Kyto V, Kallajoki M, et al. 2 003. Cardiomyocyte apoptosis in experimental coxsackievirus B3 myocarditis. Cardiovasc. Pathol. 12:255-62
124. Chow LH, Beisel KW, McManus BM. 1992. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab. Invest. 66:24-31
125. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, et al. 1997. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 276:800-6
126. Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, et al. 1998. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J. Clin. Invest. 102:1444-53
127. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, et al. 1998. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am. J. Pathol. 153:417-28
128. Joo CH, Hong HN, Kim EO, Im JO, Yoon SY, et al. 2003. Coxsackievirus B3 induces apoptosis in the early phase of murine myocarditis: a comparative analysis of cardiovirulent and noncardiovirulent strains. Intervirology 46:135-40
129. Toyozaki T, Hiroe M, Saito T, Iijima Y, Takano H, et al. 1998. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am. J. Cardiol. 81:798-800
130. Seki Y, Kai H, Kai M, Muraishi A, Adachi K, Imaizumi T. 1998. Myocardial DNA strand breaks are detected in biopsy tissues from patients with dilated cardiomyopathy. Clin. Cardiol. 21:591-96
131. Alter P, Jobmann M, Meyer E, Pankuweit S, Maisch B. 2001. Apoptosis in myocarditis and dilated cardiomyopathy: Does enterovirus genome persistence protect from apoptosis? An endomyocardial biopsy study. Cardiovasc. Pathol. 10:229-34
132. Kramer B, Huber M, Kern C, Klingel K, Kandolf R, Selinka HC. 1997. Chinese hamster ovary cells are nonpermissive towards infection with coxsackievirus B3 despite functional virus-receptor interactions. Virus Res. 48:149-56
133. Badorff C, Knowlton KU. 2004. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med. Microbiol. Immunol. 193:121-26
134. Xiong D, Yajima T, Lim B, Stenbit A, Dublin A, et al. 2007. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 115:94-102
135. Carthy CM, Yanagawa B, Luo H, Granville DJ, Yang D, et al. 2003. Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology 313:147-57
136. Huber M, Selinka HC, Kandolf R. 1997. Tyrosine phosphorylation events during coxsackievirus B3 replication. J. Virol. 71:595-600
137. Huber M, Watson KA, Selinka HC, Carthy CM, Klingel K, et al. 1999. Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication. J. Virol. 73:3587-94
138. Luo H, Yanagawa B, ZhangJ, Luo Z, Zhang M, et al. 2002. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J. Virol. 76:3365-73
139. Opavsky MA, Martino T, Rabinovitch M, Penninger J, Richardson C, et al. 2002. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J. Clin. Invest. 109:1561-69
140. Lim BK, Nam JH, Gil CO, Yun SH, Choi JH, et al. 2005. Coxsackievirus B3 replication is related to activation of the late extracellular signal-regulated kinase (ERK) signal. Virus Res. 113:153-57
141. Si X, Luo H, Morgan A, Zhang J, Wong J, et al. 2005. Stress-activated protein kinases are involved in coxsackievirus b3 viral progeny release. J. Virol. 79:13875-81
142. Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, et al. 2004. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J. Virol. 78:4289-98
143. Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, et al. 2006. Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ. Res. 99:354-61
144. Yuan J, Zhang J, Wong BW, Si X, Wong J, et al. 2005. Inhibition of glycogen synthase kinase 3β suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of β-catenin. Cell Death Differ. 12:1097-106
145. Luo H, Zhang J, Cheung C, Suarez A, McManus BM, Yang D. 2003. Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am. J. Pathol. 163:381-85
146. Meng XH, Wang Y, Zhuang JX, Han XZ, Chen Y, et al. 2004. Dynamic changes in myocardial matrix metalloproteinase activity in mice with viral myocarditis. Chin. Med. J. 117:1195-99
147. Cheung C, Luo H, Yanagawa B, Leong HS, Samarasekera D, et al. 2006. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc. Pathol. 15:63-74
148. Heymans S. 2006. Inflammation and cardiac remodeling during viral myocarditis. Ernst. Schering Res. Found Workshop 2006:197-218
149. Yang D, Yu J, Luo Z, Carthy CM, Wilson JE, et al. 1999. Viral myocarditis: identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart. Circ. Res. 84:704-12
150. Taylor LA, Carthy CM, Yang D, Saad K, Wong D, et al. 2000. Host gene regulation during coxsackievirus B3 infection in mice: assessment by microarrays. Circ. Res. 87:328-34